Technology & Science
FDA Clears First Oral GLP-1 Obesity Therapy: Wegovy Pill Gets Green Light
On 22 Dec 2025 the FDA approved Novo Nordisk’s once-daily 25 mg semaglutide tablet (Wegovy), the first GLP-1 weight-loss drug available as a pill, slated to reach U.S. pharmacies in early January 2026.